Efficacy and safety outcomes from the MATISSE phase 3 trial of maternal bivalent RSVpreF vaccination among pregnant women vaccinated at 32 to 36 weeks of gestation. Swiss Med Wkly [Internet]. 2026 Jan. 31 [cited 2026 Feb. 5];156(1):4711. Available from: https://smw.ch/index.php/smw/article/view/4711